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Background: Biologic therapies are widely used in inflammatory diseases, and they are associ-
ated to an increased infection risk, especially to granulomatous and intracellular infections
such as Legionella.
Results: A review of the literature revealed 105 cases of Legionella pneumonia in patients tak-
ing biologic therapies. Sixty-four patients (65.3%) were treated with infliximab, 23 (23.5%) with
adalimumab, 5 (5%) with etanercept and 3 (3%) with rituximab. Seventy-one per cent of the
patients were treated for rheumatologic diseases and 16% for inflammatory bowel diseases.
The majority of the patients received one or more concomitant immunosuppressive drugs,
especially steroids (43%). Overall mortality was 19%. Legionella pneumonia might complicate
therapy with biologic therapies, especially in patients being treated with infliximab or adali-
mumab given concomitantly with other immunosuppressive medications during their first 6
months of treatment.
Conclusion: Physicians should be aware of this potentially severe association. Early recognition
and treatment would likely result in reduced morbidity and mortality.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Biologic agents approved for clinical use include tumour
necrosis factor alpha inhibitors (anti-TNFa) such as eta-
nercept, infliximab, adalimumab, golimumab, and certoli-
zumab pegol; the interleukin (IL)-1 receptor antagonist,titute of Biomedical Research of
Llobregat, 08907 Barcelona, Spai
l.com (M. Bodro).
4.04.017
hts reserved.anakinra; the T-cell costimulation inhibitor, abatacept; the
humanised monoclonal antibody targeting the interleukin-6
receptor, tocilizumab; a monoclonal antibody against B-
cell-specific CD20 antigen, rituximab; a fully human
monoclonal antibody that binds to B-lymphocyte stimu-
lator, belimumab; and a monoclonal antibody which bindsBellvitge Hospital, Infectious Diseases Department, Hospital Uni-
n. Tel.: þ34 93 260 7625; fax: þ34 93 260 7637.
Table 1 Main characteristics of the reported cases.
Study name Type of study Number of
pts with
infection
Associated
disease
Biologic drug Median
age
(range)
Concomitant
immunosuppressive
drugs
Diagnostic
method
Treatment
durationa
(median,
range)
Outcomes
FDA AERS [36] Voluntary registry 68 49 rheumatologic
diseases,
9 IBD, 10 other.
Infliximab (47),
adalimumab (14),
etanercept (3),
rituximab (2),
natalizumab (1)
52
(25e85)
Steroids (21),
MTX (22), AZA (5),
other (5)
NR 4.6 months
(<1e30)
11 deaths
Tubach [7] French registry
(RATIO)
10 1IBD, 9
rheumatologic
diseases
Adalimumab (6)
Etanercept (2)
Infliximab (2)
51
(40e69)
Steroids (8)
MTX (6)
9 LAg, 1
seroconversion,2
cultures.
38.5 weeks
(3e73)
3 required ICU,
all recovered
Perez-Sola [8] Spanish
registry(BIODABASER)
,including 6969 pts
5 Rheumatic
diseases
Infliximab,
Etanercept,
adalimumab
NR NR NR 28 months 1 death
Hofmann [9] Case report 2 IBD Infliximab 42.5
(26e59)
Steroids (2/2) 2 LAg 4 weeks Both required
ICU, 1 died.
Ramos-Casals [10] Registry, including
1370 pts
1 Systemic
autoimmune
diseases
Infliximab NR NR NR NR NR
Beigel [11] Case report 1 IBD Infliximab 58 Steroids, AZA LAg, PCR NR ICU. Recovery
Kohn [21] Case report 1 IBD Infliximab 27 Steroids, AZA PCR 11 days Died from a
septic shock
Dixon [1] British registry
(BSRBR) including
9868 pts
2 RA Infliximab 54 NR NR 72 weeks
NR
Eisendle [13] Case report 1 Erytrodermic
psoriasis
Infliximab 56 Steroids Cultures (post
mortem
diagnosis)
2 weeks Died
Li Gobbi [14] Case report 1 RA Infliximab 38 MTX LAg 2 weeks recovered
Mancini [15] Case report 1 Behcet’s disease Infliximab 30 MTX NR 4 weeks recovered
Albert [22] Case report 1 RA Infliximab 73 Steroids, MTX Culture 13 months recovered
Wondergem [16] Case report 1 RA Infliximab 43 Steroids, AZA LAg 3 weeks recovered
Jinno [17] Case report 1 RA Adalimumab 67 Steroids, AZA LAg 2 years ICU,
recovered
Wuerz [23] Case report 1 RA Adalimumab 62 AZA LAg, cultures 10 weeks ICU, recovered
Favalli [37] LOHREN registry,
including 1064 pts
1 RA AntiTNFa NR NR NR NR NR
Kaku [12] Case report 1 RA Adalimumab 65 MTX LAg 2 years Died
Epping [18] Case report 1 Crohn’s
disease
Anti TNFa 26 Steroids LAg 16 months recovered
Aringer [19] Case report 1 SLE Rituximab and NR Steroids, AZA, MMF, NR 8 weeks Died
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Legionella infection related to biologics 1225to a4b1 integrin, a protein on the surface of lymphocytes,
blocking their union to the endothelial receptor,
natalizumab.
These biologic therapies are widely used in patients
treated for inflammatory diseases. Although the overall
infection risk remains a subject of open debate, some
studies have reported an increased risk of granulomatous
and intracellular infections, such as tuberculosis, listeriosis
and legionellosis [1,2]. The United States Food and Drug
Administration (FDA) has added risk of these infections as a
Boxed Warning for the entire class of TNFa inhibitors.
TNFa is synthesized by macrophages in response to
proinflammatory stimuli and acts as a central mediator of
inflammation and immune regulation. However, TNFa is
also important in host defence and plays a role in the
immune-mediated response to infection because it induces
the release of cytokines and local chemokines, leading to
attraction and stimulation of phagocytes, increased T-cell
adhesion, and enhanced antigen presentation with
recruitment and proliferation of T and B cells [3,4].
Furthermore, murine studies found a protective effect of
TNF in experimental Legionella pneumophila infections
[5,6]. Its antigenic components, especially, lipopolysac-
charide, are a strong stimulus to produce TNFa, which in-
duces a cell-mediated immune response. Rats infected with
L. pneumophila and treated with antiTNFa antagonists
showed persistent pneumonitis with a higher bacterial load,
more infected macrophages and less recruitment of pe-
ripheral blood monocytes to the lung compared to control
rats [5,6].
Given the theoretic increased risk of legionellosis in
patients receiving biologic therapies, we aimed to analyse
the association between Legionella pneumonia among
these patients. Our purpose was to characterise the clinical
presentation, duration of biologic treatment at onset of
infection, the use of concomitant immunosuppressive
medication and outcomes of the Legionella infection cases
in patients treated with biologics.Material and methods
We searched the publicly available Adverse Event Reporting
System (AERS) database of the FDA for reports of Legionella
infections with the use of biologic therapies from 2004
through the second quarter of 2011 (30 quarters in total).
AERS is a post-marketing safety database composed of
spontaneous adverse event reports to the FDA’s Sponta-
neous Reporting system (SRS) before October 1997 and re-
ports to AERS from November 1997 to present. The AERS
database includes post-marketing adverse events sponta-
neously reported from US sources and attributable post-
marketing clinical trial reports from all sources. We also
performed a PubMed search using the terms “Legionella”
and “biologics” or “tumour necrosis factor antagonists” and
included all cases reports in our analysis [1,7e25].
For our analysis we included the Medical Dictionary for
Regulatory Activities (MedDRA) term “Legionella infec-
tion”. Biologic therapies included etanercept, infliximab,
adalimumab, golimumab, certolizumab pegol, anakinra,
abatacept, tocilizumab, rituximab, belimumab and natali-
zumab. Reports were also examined for concomitant use of
1226 M. Bodro et al.immunosuppressive medications. FDA AERS reports meeting
these criteria were then imported in ASCII format into SPSS
software (version 20.0, Inc. Chicago, IL) and analytical files
were created for the final study database, including de-
mographic data, drug characteristics and outcomes. To
compare cases by biologic drugs, we used the chi-square
test with continuity correction for categorical variables
and the Student t test and ManneWhitney U-test for
continuous variables.
Results
We found 105 cases of Legionella infection, 68 of which
were from FDA AERS. Other data were from national reg-
istries (19 cases) and isolated case reports (18 cases). The
main characteristics of the reported cases are described in
Table 1. Speciation was not denoted in the FDA AERS re-
ports. In all other cases in which speciation were per-
formed, the species was L. pneumophila (30 cases).
Sixty-one per cent of the patients were males. The
median age was 52 years (range 25e87 years). North
America and Europe accounted for the bulk of reported
cases. France was the country which reported the most
episodes (27), followed by United States (10), Spain (10),
Italy (10), the United Kingdom (8), Canada (7) and Germany
(6).
Infliximab was the biologic most frequently related to
Legionella infection (65.3% of reported cases), followed by
adalimumab (23.5%), etanercept (5%), rituximab (3%),
abatacept (1%) and natalizumab (1%). One patient received
a combination of adalimumab and infliximab. Denominator
data is not available so the proportion of patients receiving
any specific biologic agent was not calculable. The majority
of the patients received one or more concomitant immu-
nosuppressive drugs, especially corticosteroids (43%),
methotrexate (35.5%), and azathioprine (13%). Rheumato-
logic diseases were the most frequent indication for
administration of biologic therapies (71%). Inflammatory
bowel disease patients accounted for 16% of the cases and
other systemic autoimmune diseases for 7%.
The median duration of biologic therapy prior to onset of
Legionella infection was 4 months (range from 0.25 to 32
months). This interval was shorter among patients who
received infliximab versus those who received etanercept
and adalimumab (1 vs. 7.6 months; p < 0.001). Forty-two
per cent of all reported cases developed within 90 days of
initiating biologic treatment.
Three patients were given inappropriate empirical
antibiotic treatment in a total of only 8 patients in whom
the initial antibiotic treatment was recorded e two of
these three patients died [9,13].
Seventeen deaths were reported from 92 patients in
whom outcome was recorded (19%). At least 9 survivors
required intensive care unit management.
Discussion
Our study underlines the relationship between biologics and
Legionella infection. This relationship was first described in
2006 by Tubach et al. [7]. They used data from the French
RATIO registry, designed to collect data on opportunisticand severe infections in patients treated with antiTNFa.
They described 10 cases of legionellosis among patients
with one year follow-up, and estimated an incidence of
33e42 cases per 100,000 patients receiving biologics, and
with a relative risk compared with that for overall popu-
lation in France between 16.5 and 21. The same group
recently published a caseecontrol analysis that supports
these high incidence rates [26]. In a review of infliximab
adverse events reported to the US FDA up until 2005, the
excess risk of infection was quantified by generating a
statistic known as the empiric Bayes geometric mean
(EBGM) and its corresponding 2-sided 90% confidence in-
terval (CI (EB05,EB95) [27]. An EB05 value of 8.7 was
discovered, implying that the drug-event pair has been
reported 8.7 times as frequently as would be expected if
reports involving the drug and reports of the event were
independent (that is, no association). In contrast, the EB05
for tuberculosis was 20.9 [27].
Infliximab, which was first approved by the FDA in 2000,
was the most commonly reported drug related to Legionella
infection, followed closely by adalimumab (2002). Only 5
published cases were associated with etanercept, approved
in 1998. More data are needed to determine the associated
risk of legionellosis in patients receiving newer biologics. It
is noteworthy that infliximab and adalimumab have a
potentially stronger relationship with legionellosis than
etanercept, in line with the study of Lanternier et al. [26].
Some studies have demonstrated higher avidity and better
stability of membrane-bound TNF with monoclonal anti-
bodies comparing to TNF receptor fusion molecule therapy.
Moreover, this difference is also observed regarding other
granulomatous and intracellular infections such as tuber-
culosis, which are significantly more frequent in infliximab
treated patients compared to etanercept. This gives more
feasibility to the difference in risk of infection between
these drugs.
Significantly, legionellosis mainly occurred in the first six
months after initiating treatment with biologics. This in-
terval was also shorter among patients who received
infliximab versus those who received etanercept and ada-
limumab (1 vs. 7.6 months, p < 0.001). Forty-two per cent
of the cases were reported <90 days after initiating of
treatment. These data are in line which other studies that
reported a decline in the infection risk over time in patients
treated with biologics. Interestingly, Strangfeld et al. ana-
lysed the RABBIT German biologic register and found that
approximately one-third of the decrease in risk was caused
by improvement in the clinical status and reduction of
concomitant steroid therapy and the other two-thirds could
be explained by selective switching of patients who were at
increased risk of infection [28].
The fact that most of the analysed cases received other
immunosuppressive therapies concomitantly is remarkable.
There are certainly other reports that describe legionellosis
in immunosuppressed patients who have not received bio-
logic therapies [29e32]. Interestingly, systemic corticoste-
roids were extensively used among these patients in similar
proportions to that in our study, suggesting that it might
have played a role in the infection. Furthermore, these
studies described a high case fatality rate, ranging from
14.3% in solid organ transplant recipients to 31% in cancer
patients, in concordance with our study which reported a
Legionella infection related to biologics 1227mortality of 19%. These rates differ from the ones reported
from community-acquired cases in non immunosuppressed
patients which are between 2.5 and 6% [33,34].
It would have been interesting to know how many cases
received inappropriate empirical antibiotic treatment and
how long it took to get the diagnosis e and if delays were
associated with increased mortality. In our analysis, only 8
cases had this kind of information and 3 of these patients
received inappropriate empirical antibiotic therapy,
resulting in 2 deaths. Although we do not have enough data
to draw conclusions, one of the factors that could
contribute our high mortality rate is a delay in diagnosis and
consequently in adequate antibiotic treatment.
Legionella infection usually occurs through inhalation of
contaminated aerosols produced by water systems such as
cooling waters, showers, hot water distribution systems and
faucets, casing sometimes community-acquired outbreaks.
The clinical manifestations of Legionnaires’ disease do not
differ much from other types of pneumonia. Diagnosis de-
pends on special laboratory tests, such as the rapid
Legionella urinary antigen test, with a sensitivity of 0.74
and specificity of 0.99 [35]. Nevertheless, it only detects L.
pneumophila serogroup 1. Definitive diagnosis is based on
cultures of the microorganism from respiratory secretions
or pleural fluid. The utility of serology is limited, except for
retrospectively proving that an infection has occurred.
Our study has some limitations. First of all, the voluntary
nature of physician reports to the FDA AERS may underes-
timate the real incidence of legionellosis. Secondly, some
reports may have been registered in the FDA AERS database
and also published or included in national registries,
therefore resulting in duplicate information. For example,
France was the country that reported most cases, almost 3-
fold comparing to United States, Spain and Italy, which
were the next countries in order of frequency. It is possible
this incidence could be overestimated if some of the cases
were reported twice. Furthermore, some information about
case reports is lacking and therefore there is limited sta-
tistical power and denominator data is not available so the
proportion of patients receiving any specific biologic agent
was not calculable.
Finally we conclude that as biologic therapies are
increasingly used to treat some inflammatory diseases we
should be aware that they may increase susceptibility to
cause certain infections such as Legionella pneumonia. The
highest risk appears to be in patients treated with infliximab
or adalimumab given concomitantly with other immuno-
suppressive medications during their first months of treat-
ment. A high index of suspicion must be maintained if this is
considered a potential cause for the patient’s clinical pre-
sentation and a urinary antigen test should be collected as
soon as possible. Rapid diagnosis and treatment ismandatory
because the presentation of legionellosis in immunocom-
promised patients can be fulminant and severe.
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